Cancer Prevention Research CR Magazine AM No Deadline
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Prevention Research 1, 182, August 1, 2008. Published Online First May 18, 2008;
doi: 10.1158/1940-6207.CAPR-07-0007
© 2008 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Perspective on This Article
Right arrow Finasteride and Prostate Cancer: New York Times Article
Right arrow All Versions of this Article:
1940-6207.CAPR-07-0007v1
1/3/182    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pinsky, P.
Right arrow Articles by Ford, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pinsky, P.
Right arrow Articles by Ford, L.
Related Collections
Right arrowCommentary

Research Articles

Estimating Rates of True High-Grade Disease in the Prostate Cancer Prevention Trial

Paul Pinsky, Howard Parnes and Leslie Ford

Authors' Affiliations: Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.

Requests for reprints: Paul F. Pinsky, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, EPN 3064, Bethesda, MD 20892. E-mail: pp4f@nih.gov.

The Prostate Cancer Prevention Trial (PCPT) showed a decreased prostate cancer rate but an increased rate of high Gleason grade disease on biopsy for finasteride versus placebo. The results from radical prostatectomy (RP) on 25% of the men undergoing RP have recently been reported and suggest that grading artifacts in biopsy Gleason scoring may have occurred. We used a statistical model to extrapolate the RP Gleason results to all men in the PCPT using a missing-at-random assumption. We estimated the rates of true high-grade (Gleason 7-10) and true low-grade disease, where true Gleason grade is what is (or would have been) found on RP. We also estimated misclassification rates on biopsy of true high-grade and low-grade disease. We show that the rate of upgrading of biopsy low-grade disease to high-grade on RP is a function of misclassification rates as well as the ratio of true low-grade to high-grade disease. The estimated relative risks for true low-grade and true high-grade disease for finasteride compared with placebo were 0.61 (95% confidence interval, 0.51-0.71) and 0.84 (95% confidence interval, 0.68-1.05), respectively. The misclassification rate of true high-grade disease (to low-grade disease on biopsy) was significantly lower for finasteride (34.6%) than for placebo (52.6%). Although misclassification rates differed, upgrading rates were similar in each arm due to the different ratios of true low-grade to high-grade disease in each arm. Results from RP show that misclassification rates on biopsy were higher in the placebo arm and that the rate of true high-grade disease may have been lower in the finasteride arm.

Key Words: Biopsy • Finasteride • Gleason Grade • Prostate Cancer • Radical Prostatectomy


Commentary

High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial
Christopher J. Logothetis and Paul F. Schellhammer
Cancer Prevention Research 2008 1: 151-152. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. R. Marshall
Keeping Our Eye on the Ball: The American Society of Preventive Oncology in 2009
Cancer Epidemiol. Biomarkers Prev., October 1, 2009; 18(10): 2796 - 2802.
[Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
J. Li and J. Kim
Molecular Profiles of Finasteride Effects on Prostate Carcinogenesis
Cancer Prevention Research, June 1, 2009; 2(6): 518 - 524.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
M. S. Lucia
Abstract CN01-02: The Prostate Cancer Prevention Trial: An update on pathology
Cancer Prevention Research, November 1, 2008; 1(7_MeetingAbstracts): CN01-02 - CN01-02.



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.